arrow
D

David G. Mutch

Washington University School of Medicine
H指数:99
被引数:4.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Germline homologous recombination deficiency influences TP53-mutant clonal hematopoiesis fitness during platinum and PARP inhibitor treatment

生殖系同源重组缺陷影响铂类和PARP抑制剂治疗期间TP53突变克隆性造血的适应性

2026-09-280
OAAI
Cervical Cancer, Version 2.2026

Abu-Rustum, N.R.; Campos, S.M.; Amarnath, S.; Arend, R.; Barber, E.; Bradley, K.; Brooks, R.; Chino, J.; Chon, H.S.; Crispens, M.A. 宫颈癌,版本2.2026,NCCN肿瘤学临床实践指南。J. Natl. Compr. Cancer Netw. 2025, 23, 549–573. [Google Scholar] [CrossRef]

2025-12-010
PRE
Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol

前瞻性评估恶性腹水细胞学在子宫内膜癌中预后意义:一项NRG Oncology/妇科肿瘤学组关于GOG-210方案的研究

2025-09-030
PRE
Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: the GOG Foundation, Inc’s Scholar Career Development Award and New Investigator Program

扩大致力于妇科肿瘤研究的临床试验研究者队伍:GOG Foundation, Inc.的学者职业发展奖和新研究者项目

2025-06-210
OAAI
Multi-center, international endometrial cancer consortium highlights

多中心、国际子宫内膜癌联盟重点内容

2025-05-010
PRE
Stromal cell DDR2 promotes ovarian cancer metastasis
2024-03-040
PRE
A combined RAD51 and phosphorylated replication protein assay predict response to platinum chemotherapy in high-grade serous ovarian cancer
2024-03-040
PRE
Vulvar Cancer, Version 3.2024
2024-03-0112
OA
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer

在1b期研究中,结合PARP和MEK抑制,有或没有anti-PD-L1,对BRCA野生型,铂敏感,复发性卵巢癌患者的主要结果和特征

CANCER
IF5.1
2024-01-301
OAAI
Cervical Cancer, Version 1.2024 Featured Updates to the NCCN Guidelines

宫颈癌,1.2024版更新了NCCN指南

2023-12-0165
OA